Spoken Alpha
ENVB
Enveric Biosciences, Inc.
Overview
Enveric Biosciences develops small-molecule neuroplastogenic therapeutics designed to treat psychiatric and neurological disorders. The company advances a pipeline of novel psychedelic-inspired compounds, including its lead candidate EB-003, which targets depression and anxiety without hallucinogenic effects.
Enveric Biosciences, Inc is a Healthcare company operating in Biotechnology with a $6.5M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 13, 2026).
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-10-04.
Transcripts
Recent earnings calls
No earnings calls indexed for ENVB yet
We index calls for roughly 3,000 US-listed companies. If you'd like us to add ENVB, reply to your welcome email and we'll prioritize it.
History
Earnings history
- Q2 FY20262026-08-13EPS$-0.76 vs ——Rev$0 vs ——EODHD
- Q1 FY20262026-05-18EPS$-1.08 vs ——Rev$0 vs ——EODHD
- Q4 FY20252026-03-26EPS$-3.81 vs ——Rev$0 vs ——EODHD
- Q3 FY20252025-11-13EPS$-10.81 vs $-0.35-100.0%Rev$0 vs ——EODHD
- Q2 FY20252025-08-13EPS$-11.65 vs $-0.35-100.0%Rev$0 vs ——EODHD
- Q1 FY20252025-05-12EPS$-4.82 vs $-0.40-100.0%Rev$0 vs ——EODHD
- Q4 FY20242025-03-27EPS$-2.03 vs $-2.76+26.5%Rev$340.4K vs ——EODHD
- Q3 FY20242024-11-13EPS$-43.20 vs $-93.60+53.8%Rev$0 vs ——EODHD
- Q2 FY20242024-08-11EPS$-45.00 vs $-99.00+54.5%Rev$0 vs ——EODHD
- Q1 FY20242024-05-14EPS$-109.80 vs $-139.50+21.3%Rev$0 vs ——EODHD
- Q4 FY20232024-03-25EPS$-1.47 vs $-1.54+4.5%Rev$647.1K vs ——EODHD
- Q3 FY20232023-11-12EPS$-287.12 vs $-376.20+23.7%Rev$0 vs ——EODHD
- Q2 FY20232023-08-10EPS$-450.42 vs $-117.00-100.0%Rev$0 vs ——EODHD
- Q1 FY20232023-05-14EPS$-4.24 vs $-2.23-89.9%Rev$0 vs ——EODHD
- Q4 FY20222023-03-30EPS$-344.11 vs $-525.60+34.5%Rev$0 vs ——EODHD
- Q3 FY20222022-11-13EPS$-582.21 vs $-720.00+19.1%Rev$0 vs ——EODHD
- Q2 FY20222022-08-11EPS$-818.08 vs $-675.00-21.2%Rev$0 vs ——EODHD
- Q1 FY20222022-05-12EPS$-990.00 vs $-1080.00+8.3%Rev$0 vs ——EODHD
- Q4 FY20212022-03-30EPS$-89.00 vs $-8.00-100.0%Rev$0 vs ——EODHD
- Q3 FY20212021-11-14EPS$-1080.00 vs $-1260.00+14.3%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-13 | $-0.76 | — | — | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-18 | $-1.08 | — | — | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-26 | $-3.81 | — | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-10.81 | $-0.35 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-11.65 | $-0.35 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-4.82 | $-0.40 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-27 | $-2.03 | $-2.76 | +26.5% | $340.4K | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-43.20 | $-93.60 | +53.8% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-45.00 | $-99.00 | +54.5% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-109.80 | $-139.50 | +21.3% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-25 | $-1.47 | $-1.54 | +4.5% | $647.1K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-287.12 | $-376.20 | +23.7% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-10 | $-450.42 | $-117.00 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-4.24 | $-2.23 | -89.9% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-344.11 | $-525.60 | +34.5% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-582.21 | $-720.00 | +19.1% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-11 | $-818.08 | $-675.00 | -21.2% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-12 | $-990.00 | $-1080.00 | +8.3% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-89.00 | $-8.00 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-1080.00 | $-1260.00 | +14.3% | $0 | — | — | EODHD |
Source: EODHD. ENVB reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
- Joseph Edward TuckerCEO5 yr 2 mono recorded callsCurrent
- Kevin Michael CoveneyCFO3 yr 8 mono recorded callsCurrent
- Peter J FacchiniChief Innovation Officer3 yr 10 mono recorded callsCurrent
- David Ian JohnsonCEO2 mono recorded callsFormer
- Brent KeltonCEO1 yr 2 mono recorded callsFormer
- Giri DevanurCEO2 yr 6 mono recorded callsFormer
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ENVB.
$ curl https://api.spokenalpha.com/v1/companies/ENVBFAQ
Frequently asked about ENVB
Where can I find Enveric Biosciences, Inc.'s (ENVB) earnings call transcripts?
Spoken Alpha indexes ENVB's earnings call transcripts at https://spokenalpha.com/companies/ENVB. Each call links to attributed speakers and parsed analyst Q&A. Enveric Biosciences, Inc.'s own investor relations page is at https://www.enveric.com/investors/.
What sector is ENVB in?
Enveric Biosciences, Inc. (ENVB) operates in the Healthcare sector (Biotechnology industry).